- Home
- YHGJ vs QNRX Comparison
YHGJ vs QNRX Comparison
Compare YHGJ & QNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | YHGJ | QNRX |
|---|---|---|
| Founded | 1975 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Chemicals | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.2M | 10.1M |
| IPO Year | 1997 | N/A |
Fundamental Metrics
Financial Performance| Metric | YHGJ | QNRX |
|---|---|---|
| Price | $3.98 | $13.15 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 19.6K | ★ 49.8K |
| Earning Date | 11-13-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $19,377,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 4.41 | N/A |
| 52 Week Low | $3.37 | $5.01 |
| 52 Week High | $12.70 | $41.80 |
Technical Indicators
Market Signals| Indicator | YHGJ | QNRX |
|---|---|---|
| Relative Strength Index (RSI) | 44.36 | 47.20 |
| Support Level | $3.53 | $13.42 |
| Resistance Level | $3.99 | $14.25 |
| Average True Range (ATR) | 0.28 | 0.98 |
| MACD | -0.02 | 0.03 |
| Stochastic Oscillator | 54.78 | 34.02 |
Price Performance
Historical ComparisonAbout YHGJ Yunhong Green CTI Ltd.
Yunhong Green CTI Ltd manufactures and marketers of foil balloons and produces laminated and printed films for commercial uses. The company also distributes balloon-inspired and other gift items, and continues development of compostable material solutions, and markets its products throughout the United States and in several other countries.
About QNRX Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.